Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.300
0.00 (0.00%)
May 5, 2026, 4:00 PM EDT - Market closed
Company Description
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand.
Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Aug 13, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Gerald Proehl |
Contact Details
Address: 3525 Del Mar Heights Rd., Suite 332 San Diego, California 92130 United States | |
| Phone | 858 800 2543 |
| Website | dermatarx.com |
Stock Details
| Ticker Symbol | DRMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $7.00 |
| CIK Code | 1853816 |
| CUSIP Number | 249845504 |
| ISIN Number | US2498455045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gerald T. Proehl | Founder, President, Chief Executive Officer and Chairman |
| David F. Hale | Co-Founder and Lead Independent Director |
| Dr. Christopher J. Nardo M.P.H., Ph.D. | Senior Vice President and Chief Development Officer |
| Sean Proehl | Associate General Counsel |
| Kyra Peckaitis | Vice President of Marketing |
| Dr. Maria Bedoya Toro Munera M.B.A., Ph.D. | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2026 | SCHEDULE 13G/A | Filing |
| Apr 17, 2026 | ARS | Filing |
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 26, 2026 | 10-K | Annual Report |
| Mar 26, 2026 | 8-K | Current Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 23, 2026 | SCHEDULE 13D/A | Filing |
| Feb 18, 2026 | SCHEDULE 13G/A | Filing |